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Abstract
Background: The availability of multiple new treatments formetastatic castration-resis-
tant prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a
response. A decline in prostate-specific antigen (PSA) iswidely used tomonitor treatment
response, but is not validated as an intermediate endpoint for overall survival (OS).
Objective: To evaluate the association between early PSA decline and OS following
abiraterone acetate (AA) treatment.
Design, setting, and participants: We identiﬁed mCRPC patients treated with AA before
or after docetaxel at the Royal Marsden NHS Foundation Trust between 2006 and
2014. Early PSA decline was deﬁned as a 30% decrease in PSA at 4 wk relative to
baseline, and early PSA rise as a 25% increase.
Outcomemeasurements and statistical analysis: AssociationwithOSwasanalyzedusing
multivariate Cox regression and log-rank analyses. Spearman’s rho correlation coefﬁcient
(r) was calculated to evaluate the association between PSA changes at 4 wk and 12 wk.
Results and limitations: There were 274 patients eligible for this analysis. A 30% PSA
decline at 4 wk was associated with longer OS (25.8 vs 15.1 mo; hazard ratio [HR] 0.47,
p < 0.001), and a 25% PSA rise at 4wkwith shorter OS (15.1 vs 23.8mo;HR 1.7, p = 0.001)
in both univariate and multivariable models. The percentage PSA decline at 4 wk was
signiﬁcantly correlated with the percentage PSA change at 12 wk (r = 0.82; p < 0.001).
Patients achieving a 30% PSA decline at 4 wk were 11.7 times more likely to achieve a
50% PSA decrease at 12 wk (sensitivity 90.9%, speciﬁcity 79.4%). Limitations include the
retrospective design of this analysis.
Conclusions: Patients not achieving 30% PSA decline after 4 wk of AA have a lower
likelihood of achieving PSA response at 12 wk and signiﬁcantly inferior OS. Prospective
multicentre validation studies are needed to conﬁrm these ﬁndings.
Patient summary: Prostate-speciﬁc antigen (PSA) is commonly used to evaluate re-
sponse to treatment in metastatic castration-resistant prostate cancer. Expert recom-
mendations discourage reliance on PSA changes earlier than 12 wk after treatment
initiation. Our data sug
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Prostate cancer (PCa) is the most common malignancy in
men and the second leading cause of death from cancer
[1]. Almost 34% of men for whom radical treatment fails
develop incurable metastatic disease [2]. Androgen depri-
vation is the mainstay of therapy for advanced PCa, but
progression to a castration-resistant state invariably occurs
after a median time of 18–24mo [3], while the median time
from diagnosis of metastatic disease to death is 40.7 mo
[4]. Evaluation of treatment responses in metastatic PCa
remains challenging [5]. Bone represents the likeliest site of
metastases, and almost 90% of patients have radiologic
evidence of bone metastases [6,7], but this is non-evaluable
according to Response Evaluation Criteria in Solid Tumors
(RECIST) [8]. The consensus criteria of the Prostate Cancer
Working Group (PCWG2) are used to report PCa outcomes
in clinical trials. These rely on a composite measure of
clinical, radiologic, and serologic (prostate-specific antigen
[PSA] changes) outcomes to define response to treatment
and progression [9].
PSA continues to be widely used to monitor PCa
[10,11]. PCWG2 criteria recommend reporting PSA response
as a continuous variable in the form of waterfall plots,
although both 30% and 50% PSA declines are also commonly
reported, usually at nadir and at 12 wk, and both are
associated with improved survival [9]. A 30% PSA decline
consistently has a stronger association with survival than a
50% PSA decline [12–14]. Similarly, PSA progression
according to PCWG2 criteria is associated with shorter
survival [15,16]. Despite this, studies have not validated PSA
decline as a surrogate of overall survival (OS), although a
recently published pooled analysis of the COU-301 and
COU-302 trials indicated that PSA kinetics, including PSA
doubling time, satisfied the Prentice criteria for OS
surrogacy [17].
Defining the best time to assess response is also
challenging. According to PCWG2 criteria, progression
should not be determined during the first 12 wk because
of late responses and flare reactions [9,18,19]. Insufficient
data have therefore been reported regarding the clinical
relevance of early PSA changes in mCRPC patients treated
with abiraterone acetate (AA) [20].We hypothesized that an
early decline in PSA by 30% after 4 wk of treatment with
AA is associated with improved OS and a 50% PSA decline at
12 wk, and that a PSA increase of 25% after 4 wk of
treatment is associate with much poorer outcome and a
high likelihood of a 50% PSA increase at 12 wk. If confirmed,
these data could guide future studies on earlier treatment
termination for insensitive disease.
2. Patients and methods
2.1. Study design and data collection
Patients with biochemically or histologically conﬁrmed progressive
mCRPC and castrate levels of testosterone treated with AA outside of
clinical trials at the Royal Marsden NHS Foundation Trust between
January 2006 and December 2014 were considered eligible for analysis.Additional inclusioncriteriawere theavailabilityofPSAdataat4and12wk
after AA treatment initiation. A physical examination, including Eastern
CooperativeOncologyGroupperformancestatus (ECOGPS),and laboratory
studies, including a full blood count, routine biochemistry comprising
albumin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and
PSA, were carried out at baseline and at visits every 4 wk. Patients were
reviewed every 4 wk until disease progression occurred or treatment was
discontinued for other reasons. Radiographic evaluation with computed
tomography and bone scans was performed every 12–16 wk.
2.2. Endpoint definition
OS was deﬁned as the time between treatment initiation and either the
date of death or of last follow-up for surviving patients. PSA decline
endpoints evaluated were consistent with published consensus guide-
lines [9]. PSA response at 12 wk was deﬁned as either a 30% or a 50%
decline in PSA relative to baseline, conﬁrmed by a second reading at least
3wk later. Early PSA responsewas deﬁned as a 30% decline in PSA at 4wk
relative to baseline. Early and 12-wk PSA declineswere also calculated as
a continuous value, expressed as the percentage decline relative to
baseline. PSA progression at 12wkwas deﬁned as a 25% increase relative
to baseline or, in cases with an initial PSA decline, relative to nadir, and a
minimum PSA level of 2 ng/ml, conﬁrmed by a second reading at least
3 wk later. Early PSA progression was deﬁned as a 25% increase at 4 wk
relative to baseline.
2.3. Statistical analysis
Results are presented as the median and interquartile range (IQR) for
continuous variables and as number and percentage frequency for
categoricalvariables. Kaplan-Meieranalysiswasused toestimate survival.
Association between PSA changes (response and/or progression) and
survival was evaluated in univariable and multivariable Cox regression
models. Continuous variables with skewed distributions (PSA, LDH, ALP)
were log-transformed. Only variables with a signiﬁcant association with
outcome (p < 0.05) in univariable analysis were selected for testing in
multivariable models. Spearman’s rho correlation coefﬁcient (r) was
calculated to assess the association between thepercentage PSA decline at
4 and 12 wk. The association between early PSA changes (response or
progression) and PSA response or progression at 12 wk was evaluated
using logistic regression models. We calculated odds ratios (ORs) and risk
ratios (RRs) and the corresponding95% conﬁdence interval (CI). Sensitivity
and speciﬁcity analyses were performed. To calculate predictive values,
PSA response rates for the COU-301 and COU-302 trials were used for the
postchemotherapy andprechemotherapy cohorts, respectively, as recent-
ly reported [21,22]. Statistical analyseswereperformedusingSPSS version
20 (IBM, Armonk, NY, USA).
3. Results
3.1. Patient characteristics
Between January 2006 and December 2014, 488 patients
were treatedwith AA at the Royal Marsden NHS Foundation
Trust. Of these, 274 patients were treated outside a clinical
trial with valid baseline, week 4, and week 12 PSA values,
and were therefore eligible for this analysis; 117 and
157 patients received AA before and after chemotherapy,
respectively (Supplementary Fig. 1). The clinical character-
istics are summarized in Table 1. Postchemotherapy
patients had significantly higher PSA, ALP, and neutrophil
to lymphocyte ratio, significantly lower hemoglobin and
Table 1 – Patient characteristics and outcome a
Characteristics All patients Prechemotherapy
cohort
Postchemotherapy
cohort
p value
Number (n) 274 117 157
Prostate-speciﬁc antigen [2_TD$DIFF]mg/l 132 (40–409) 61 (25–194) 259 (77–668) 0.000
Hemoglobin [3_TD$DIFF]g/l 11.8 (10.4–12.9) 12.5 (11.2–13.6) 11.1 (10.1–12.6) 0.002
Albumin [4_TD$DIFF]g/l 35 (32–38) 37 (34–39) 35 (31–37) 0.001
Alkaline phosphatase [5_TD$DIFF]U/l 131 (70–303) 106 (65–202) 165 (82–348) 0.000
Lactate dehydrogenase [6_TD$DIFF]U/l 182 (152–243) 174 (151–223) 196 (154–272) 0.055
Neutrophil to lymphocyte ratio 3.5 (2.4–5.5) 3.2 (2.1–4.4) 3.7 (2.5–6.4) 0.009
ECOG PS, n (%)
0–1 [7_TD$DIFF]244 ( [8_TD$DIFF] 9.1) [9_TD$DIFF]113 ( [10_TD$DIFF]96.6) [11_TD$DIFF] 31 ( [12_TD$DIFF]83.4) 0.006
2–3 [13_TD$DIFF]24 ( [14_TD$DIFF]8.8) [15_TD$DIFF]2 ( [16_TD$DIFF] .7) [17_TD$DIFF]22 ( [18_TD$DIFF] 4)
Metastases, n (%) 0.167
Bone 117 (42.7) 51 (43.6) 66 (42)
Bone + lymph nodes 92 (33.6) 34 (29.1) 58 (36.9)
Bone + lymph nodes + visceral 11 (4) 2 (1.7) 9 (5.7)
Lymph nodes 26 (9.5) 16 (13.7) 10 (6.4)
Lymph nodes + visceral 2 (0.7) 2 (1.7) 0
Visceral 2 (0.7) 0 2 (1.3)
None 11 (4) 7 (6) 4 (2.5)
Pain, n (%) 0.000
Yes [19_TD$DIFF]72 ( [20_TD$DIFF] 8.1) [21_TD$DIFF] 5 ( [22_TD$DIFF]12.8) [23_TD$DIFF]62 ( [24_TD$DIFF]39.5)
No [25_TD$DIFF]170 ( [26_TD$DIFF] 2) [27_TD$DIFF]90 ( [28_TD$DIFF]76.9) [29_TD$DIFF]80 ( [30_TD$DIFF]56.3)
Outcome All patients Prechemotherapy
cohort
Postchemotherapy
cohort
OR (95% CI)
[p value]
30% PSA response at 12 wk, n (%) 0.39 (0.24–0.64)
[<0.001]
Conﬁrmed 121 (44.2) 67 ( [31_TD$DIFF]57.3) 54 (34.4)
Unconﬁrmed 14 (5.1) 4 (3.4) 10 (6.4)
No response 139 (50.7) 46 (39.3) 93 (59.2)
50% PSA response at 12 wk, n (%) 0.41 (0.25–0.68)
[0.001]
Conﬁrmed 99 (36.1) 56 (47.9) 43 (27.4)
Unconﬁrmed 9 (3.3) 3 (2.5) 6 (3.8)
No response 166 (60.6) 58 (49.6) 108 (67.5)
PSA progression at 12 wk, n (%) 64 (23.4) 21 (17.9) 43 (27.4) 1.7 (0.96–3.11)
[0.068]
Survival, mo (95% CI) 19.8 (16.5–23.1) 36.4 (24.3–48.5) 13.3 (10.9–15.8) 2.8 (2.01–3.89)
[<0.001]
a Data for continuous variables are presented as median (interquartile range).
CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; OR = odds ratio.
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comparison to the prechemotherapy cohort. There was no
difference in metastatic disease distribution. The overall
median follow-up was 14.6 mo (IQR 9–20.6); 181 patients
(66.1%) had died by last follow-up, 58 (49.6%) in the
prechemotherapy and 123 (76.9%) in the postchemotherapy
cohort. Median OS was 19.8 mo (95% CI 16.5–23.1) and was
longer in the prechemotherapy cohort (HR 2.8, 95% CI 2–
3.9; Table 1). The median PSA change at 12 wk was –25%
(IQR –73.8% to +40.7%); 135 patient (49.3%) achieved a 30%
PSA decline and 108 (39.4%) a 50% PSA decline. [44_TD$DIFF] Confirmed
PSA declines were commoner in the prechemotherapy
group ([45_TD$DIFF] 7.3% vs 34.4%; p < 0.001). Sixty-four patients
(23.4%) had confirmed PSA progression at 12 wk; the rate
of PSA progression was higher in the postchemotherapy
cohort (27.4% vs17.9%; p = 0.068; Table 1).
3.2. PSA decline at 4 wk after AA treatment initiation
The median PSA change at 4 wk after treatment initiation
was –21.2% (IQR –58% to +21.9%), and 126 patients (46%)achieved a 30% PSA decline at 4 wk. Early PSA decline was
more frequent in the prechemotherapy cohort (52.1% vs
41.4%; p = 0.078). Overall, a 30% PSA decline at 4 wk was
associated with substantially longer OS (25.8 vs 15.1 mo;
HR 0.47, p < 0.001; Fig. 1A) in univariable andmultivariable
Cox regression models (Table 2 and Supplementary
Table 1). Similar results were observed when analyzing
the postchemotherapy and prechemotherapy cohorts sep-
arately (Table 2, Fig. 1B,C).
Moreover, out of 126 patients with a 30% PSA decline at
4wk, 106 (84.1%) achieved a confirmed 30% PSA decline and
90 (71.4%) a confirmed 50% PSA decline at 12 wk. Critically,
among patients without a PSA decline at 4 wk, only 15
(10.1%) and nine (6.1%) had confirmed 30% and 50% PSA
declines, respectively, at 12 wk. Moreover, the percentage
PSA decline at 4 wk was significantly correlated with the
percentage PSA change at 12 wk (r = 0.82; p < 0.001).
Similar findings were observed for both the prechemother-
apy and postchemotherapy cohorts (Table 3). Furthermore,
patients achieving a 30% PSA decline at 4 wk were 8.3 times
more likely to have a 30% PSA decline at 12 wk, and
[(Fig._1)TD$FIG]
Fig. 1 – Kaplan-Meier curves for overall survival (OS) for a decrease in prostate-specific antigen of I30% at 4 wk as a dichotomous variable: (A) overall
study population, (B) post-chemotherapy population, and (C) pre-chemotherapy population. CI = confidence interval; HR = hazard ratio calculated from
Cox regression models.
E U RO P E AN URO LOG Y 7 0 ( 2 0 1 6 ) 7 2 4 – 7 3 1 72711.7 times more likely to have a 50% PSA decline at 12 wk.
Early PSA response had sensitivity of 87.6% (95% CI 80.6–
92.3%) and specificity of 86.9% (95% CI 80.7–91.4%) for
detection of a 30% PSA response at 12 wk (Table 4), and
sensitivity of 90.9% (95% CI 83.6–95.1%) and specificity of
79.4% (95% CI 72.8–84.8%) for detection of a 50% PSA
response at 12 wk.
We defined the positive predictive value (PPV) as the
probability of achieving a biochemical response at 12wk for
patients with an early PSA decline, and the negative
predictive value (NPV) as the probability that patients with
no decline at 4 wk will lack a 12-wk PSA response. We used
the PSA data reported in the COU-301 (45.9%) and COU-302
(74.2%) trials for the prevalence of a 12-wk PSA response in
the postchemotherapy and prechemotherapy cohorts,
respectively. Early PSA response had PPV of 85.5% and95.2%, and NPV of 94.8% and 63.1% for the postchemother-
apy and prechemotherapy cohorts, respectively (Table 4).
3.3. Rising PSA at 4 wk after AA treatment initiation
Overall, 102 patients (37.2%) experienced a 25% PSA rise
after 4 wk of AA, of whom 36/117 were (30.8%) in the
prechemotherapy group and 66/157 (42%) in the post-
chemotherapy group (nonsignificant trend, p = 0.056).
Patients with an early 25% PSA rise had significantly shorter
OS than those without a 25% PSA rise (15.1 vs 23.8 mo; HR
1.7, 95% CI 1.3–2.4; p = 0.001) in both univariable and
multivariable models (Table 2, Supplementary Table 2). A
25% PSA rise after 4wkwas associatedwith poorer outcome
in both the prechemotherapy and postchemotherapy
cohorts (Table 2).
Table 2 – Early prostate-specific antigen (PSA) response or progression and survival
n (%) Survival (mo) HR (95% CI) p value
Early PSA response
All patients
30% PSA response 126 (46) 25.8 (20–31.5) 0.47 (0.35–0.65) <0.001
<30% PSA response 148 (54) 15.1 (11.1–19.2)
Postchemotherapy cohort
30% PSA response 65 (41.4) 18.9 (14.5–23.2) 0.57 (0.39–0.83) 0.003
<30% PSA response 92 (58.6) 10.4 (8.7–12.1)
Prechemotherapy cohort
30% PSA response 61 (52.1) 43.6 (35.4–51.8) 0.43 (0.25–0.76) 0.004
<30% PSA response 56 (47.9) 21.5 (14.2–28.7)
Early PSA progression
All patients
PSA progression 10 (37.2) 15.1 (9.7–20.6) 1.73 (1.26–2.37) 0.001
No PSA progression 172 (62.8) 23.8 (19.1–28.5)
Postchemotherapy cohort
PSA progression 66 (42) 10.3 (8.1–12.5) 1.85 (1.17–2.92) a [1_TD$DIFF] 0.008
No PSA progression 91 (58) 16.3 (13.6–19)
Prechemotherapy cohort
PSA progression 36 (30.8) 21.4 (14.7–28.2) 2.43 (1.24–4.76) b 0.009
No PSA progression 81 (69.2) 43.6 (28.6–58.7)
CI = conﬁdence interval, HR = hazard ratio.
a Multivariable model for postchemotherapy cohort including baseline PSA (log-transformed), hemoglobin, albumin, alkaline phosphatase (log-transformed),
lactate dehydrogenase (log-transformed), neutrophil to lymphocyte ratio (log-transformed), Eastern Cooperative Oncology Group performance status, and pain.
b Multivariable model for prechemotherapy cohort including baseline alkaline phosphatase (log-transformed), lactate dehydrogenase (log-transformed), and
Eastern Cooperative Oncology Group performance status.
Table 3 – Prostate-specific antigen (PSA) response at 4 wk and 12 wk
30% PSA response
at 4 wk, n (%)
RR
(95% CI)
p value
No Yes
All patients
30% PSA response at 12 wk
No response 133 (89.9) 20 (15.9) 8.3 (5.1–13.5) <0.001
Response 15 (10.1) 106 (84.1)
50% PSA response at 12 wk
No response 139 (93.9) 36 (28.6) 11.7 (6.1–22.3) <0.001
Response 9 (6.1) 90 (71.4)
Postchemotherapy cohort
30% PSA response at 12 wk
No response 89 (96.7) 14 (21.5) 24.1 (7.8–73.7) <0.001
Response 3 (3.3) 51 (78.5)
50% PSA response at 12 wk
No response 91 (98.9) 23 (35.4) 59.4 (8.4–421) <0.001
Response 1 (1.1) 42 (64.6)
Prechemotherapy cohort
30% PSA response at 12 wk
No response 44 (78.6) 6 (9.8) 4.2 (2.5–7) <0.001
Response 12 (21.4) 55 (90.2)
50% PSA response at 12 wk
No response 48 (85.7) 13 (21.3) 5.5 (2.9–10.6) <0.001
Response 8 (14.3) 48 (78.7)
CI = conﬁdence interval; RR = relative risk.
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(48%) experienced confirmed PCWG2 PSA progression
(25% increase) at 12 wk; this early PSA rise was
significantly associated with confirmed progression at
12 wk (p < 0.001). Patients experiencing a 25% PSA rise at
4 wk were 5.5 times more likely to have PCWG2 PSA
progression at 12 wk (Table 5). Of the patients with a 25%
PSA rise at 4 wk, nine (8.8%) and four (3.9%) achievedconfirmed 30% and 50% PSA responses, respectively, after
12 wk on AA. An early 25% PSA rise at 4 wk remained
significantly associated with 12-wk PCWG2 PSA progres-
sion for the postchemotherapy and prechemotherapy
cohorts (Table 5). A 25% PSA rise at 4 wk had sensitivity of
76.6% (95% CI 64.9–85.3%) and specificity of 74.8% (95% CI
68.5–80.2%) for detection of confirmed progression at
12 wk (Table 4).
Table 4 – Sensitivity, specificity, and predictive value a [33_TD$DIFF] of early (4 wk) PSA response and progression
Sensitivity, %
(95% CI)
Speciﬁcity, %
(95% CI)
PPV, %
(95% CI)
NPV, %
(95% CI)
All patients
30% PSA response 87.6 (80.6–92.3) 86.9 (80.7–91.4)
PSA progression 76.6 (64.9–85.3) 74.8 (68.5–80.2) – –
Postchemotherapy cohort
30% PSA response 94.4 (84.9–98.1) 86.4 (78.5–91.7) 85.5 (78.3–90.6) 94.8 (85.9–98.2)
PSA progression 30.9 (20.3–44) 83.3 (74.9–89.3) – –
Prechemotherapy cohort
30% PSA response 82.1 (71.3–89.5) 88 (76.2–94.3) 95.2 (90.2–97.7) 63.1 (50.3–74.2)
PSA progression – –
PSA = prostate-speciﬁc antigen; CI = conﬁdence interval, NPV = negative predictive value, PPV = positive predictive value.
a To estimate the PPV and NPV of a 30% PSA response, the prevalence was estimated using the rates of 30% PSA response at 12 wk for the COU-301
(postchemotherapy cohort) and COU-302 (prechemotherapy cohort) trials, respectively.
Table 5 – Prostate-specific antigen (PSA) progression at 4 and 12 wk
PSA progression at 12 wk, n (%) RR (95% CI) p value
No Yes
All patients
No PSA progression at 4 wk 157 (91.3) 15 (8.7) 5.5 (3.3–9.3) <0.001
PSA progression at 4 wk 53 (52) 49 (48)
Postchemotherapy cohort
No PSA progression at 4 wk [36_TD$DIFF]81 ( [37_TD$DIFF]89) [38_TD$DIFF]10 ( [39_TD$DIFF]11) 4.5 (2.4–8.6) <0.001
PSA progression at 4 wk [40_TD$DIFF]33 ( [41_TD$DIFF]50) [42_TD$DIFF]33 ( [43_TD$DIFF]50)
Prechemotherapy cohort
No PSA progression at 4 wk 76 (93.8) 5 (6.2) 7.2 (2.9–18.1) <0.001
PSA progression at 4 wk 20 (55.6) 16 (44.4)
CI = conﬁdence interval; RR = relative risk.
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Better tools to assess treatment responses are needed to
improve care for patients with advanced PCa, with patients
currently receiving 12wk of a new treatment before a switch
decision ismade owing to challenges in imaging bonedisease
[23]. Treatment switch decisions are frequently driven by
alternativebiomarkers (particularlyPSA)and symptoms; this
impacts progression-free survival measures, which may not
always correlate with OS [24]. Post-treatment PSA changes
correlate with prognosis but are not validated as a surrogate
for survival [14–16]. Nonetheless, monthly PSA tests during
treatment are commonly used to monitor responses, with a
recent survey indicating that specialists frequently advise
treatment switches before 12 wk on a novel treatment have
elapsed [25]. Assessing PSA changes in the first 12 wk of
treatment with novel androgen receptor (AR) signaling
inhibitors is therefore of major practical relevance to routine
patient care. We arguably describe the first correlation
between PSA decline after 4 wk of AA + prednisolone
treatment and outcome. We report that a PSA decline of 30%
and PSA rise of 25% after only 4wkofAA+prednisolone could
identify patientswhomay ormay not be benefitting fromAA
treatment, indicating a need for further validation studies to
evaluate this critically important question.
Overall, we report that patients with a PSA decline of 30%
at 4wk have substantially longer OS, with an 8.3-fold higher
likelihood of a response at 12 wk. Of these patients, 78.5%
and 90% in the prechemotherapy and postchemotherapy
populations, respectively, had a 50% PSA decline at 12 wk.Conversely, only 15.9% of patients with a 30% PSA decline at
4 wk did not meet the response criteria at 12 wk (Table 3).
However, concerns regarding misinterpretation of such
early PSA changes have been raised because of late
decreases in PSA reported for 20% of mCRPC patients
treated with docetaxel [26] and cabazitaxel [19]. This
phenomenon, described by some as PSA flare, may not be
associated with a worse outcome [19]. Indeed, in a post hoc
analysis of TAX-327 it was estimated that PSA flare (defined
as any PSA rise not reaching the progression criterion or a
rise that satisfied the progression criterion but with a later
measurement that was <50% of the baseline value)
occurred in 16.7% of patients [18]. However, drugs targeting
AR signaling, such as abiraterone and enzalutamide, may
have a very different relationship to early PSA decreases,
since PSA is a excellent pharmacodynamic biomarker of AR
signaling in the absence of aberrations of the PSA promoter
or key regulators of PSA production and secretion [27].
Conversely, we report that a 25% PSA rise at 4 wk was
associated with a 5.5-fold higher likelihood of biochemical
progression at 12 wk. Overall, only nine (3.2%) and four
(1.5%) patients with a 25% PSA rise at 4wk achieved 30% and
50% PSA decreases, respectively, at 12 wk; this early PSA
increase was associated with worse prognosis in preche-
motherapy (21.4 vs 43.6 mo; HR 1.85, 95% CI 1.17–2.92;
p < 0.009) and postchemotherapy (10.3 vs 16.3 mo; HR
2.43, 95% CI 1.24–4.76; p < 0.008) cohorts. The frequency of
a 25% PSA rise at 4 wk was similar in the prechemotherapy
and postchemotherapy populations, possibly reflecting the
30% of patients with AA-refractory disease regardless of
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response is very uncommon after a 25% PSA rise at 4 wk. A
previous retrospective study reported an 8.7% (9/103) flare
rate on AA as second-line treatment [20]. Our data may
differ because of our more stringent definition of flare, in
accordance with PCWG criteria.
Finally, this study is limited by its retrospective nature
and requires further validation in prospective studies.
Moreover, it involved outcomes for patients at a single
institution, so confirmation, preferably in multicentre
international studies, is required.
5. Conclusion
PSA changes as early as 4 wk after AA initiation are highly
associated with OS and PSA response at 12 wk in both
prechemotherapy and postchemotherapy (docetaxel) set-
tings. PSA flare is uncommon following AA. Prospective
trials are now warranted to further validate these findings
to give clinicians robust data that can assist them with
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